- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02174380
Effectiveness of Active Case Finding of Household Contacts in a Routine Tuberculosis (TB) Control Program
Cost-effectiveness of a Population-based Active TB Control Program for Tuberculosis, Lima, Peru
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Ministry of Health TB program of the District SJL (DISA NTP) is undertaking new public health intervention that involves the active evaluation of household contacts. We are collaborating to roll this intervention out as a stepped wedge pragmatic randomized controlled trial in order to evaluate the effectiveness and cost-effectiveness of this intervention.
Intervention Model
The intervention is rolled out across all clusters (or health centres) in the form of a stepped wedge design, that is a unidirectional crossover, such that all clusters start in the control arm and are then randomized to the time point of cross over to the intervention arm. This continues in steps until all clusters (or health centres) have crossed over to the intervention arm. The randomization of health centres is to the timepoint at which they will cross over to the intervention arm. This randomization was stratified by clinicTB rates <100/100,000, TB rates 100 to 200/100,000, and clinics with TB rates >200/100,000, to ensure balance of clinic sizes randomized to the intervention arm at each time point.
Power analysis
Given that the number of clusters, or health centres (n=35) is fixed, a power analysis was undertaken to estimate the smallest detectable difference between the overall yields of the active intervention (ACF) and the passive case finding (PCF) in the current study. The power analysis for stepped wedge clustered designs must be modified to account for the stepped implementation and the variation in cluster sizes we are likely to observe. In a parallel study designed to achieve a specified level of power, the same population in a stepped wedge design will have less the specified level of power, and the standard normal deviates should be increased by an inflation factor. Using a similar approach and accounting for stepped wedge design and the varying cluster sizes within the sample, in comparison to the expected baseline 1% case detection among household contacts we anticipate in passive case finding, we should have a power of greater than 90% detect differences between 3% and 4% ( with overall yields of ACF with 4 or 5%) between the intervention and control arms. Based on previous studies, we anticipate this should be adequate to determine an effect that would be of clinical and programmatic importance.
The study will be undertaken in district clinics over the course of 18 months (3 baseline and 15 months of the ACF program phase-in). In 2010, DISA NTP reported 1,871 TB cases within 35 clinics over 12 months (unpublished Ministry of Health data). We anticipate median of 5 household contacts per TB case (range 3-7) . In previous studies within the district, response rates to index case enrollment to studies in the district have been over 80%. In a study recruiting 60 Multidrug resistant (MDR) TB index cases and 80 randomly selected drug-sensitive TB controls in SJL, 92% of case and 98% of controls selected agreed to participate in the study. Therefore, given our current proposed roll out over 15 months, if we conservatively estimate 70% participation and 3 household contacts per home we would anticipate approximately 1900 index TB cases and approximately 5700 household contacts.
Data extraction and management
DISA NTP routinely collect data on household contacts evaluated in public health forms within TB case histories. Similarly, during home visits, additional ACF forms on household contacts will be collected. The new ACF TB forms are public health forms that DISA NTP has developed, however with input from the study investigators, both to ensure data completeness and quality and to incorporate any data on time and cost of the program. The study investigators will provide a role in pilot testing and validation of the data collection tools and program procedures. DISA NTP staff will conduct all home visits, all evaluations TB cases and contacts and related data collection. Currently all NTP data at the clinic level are paper-based and maintained in individual TB case charts.
Study specific teams (university-based) will audit and extract the routine public health and the active intervention TB forms. This strategy will ensure a real-life pragmatic perspective of the program using DISA NTP staff to implement the program in the context of their regular TB program, however provide additional monitoring and digitizing of data for evaluation. Dedicated study field workers will extract PCF and ACF data prospectively from the original TB case histories, household contact evaluation and ACF intervention (where applicable) forms within index TB patient charts at DISA NTP clinics. Information from the case histories for each TB patient's household contacts will be collected in the first month, at 3 months and 6 month time periods. The extraction method will include where possible and allowed photocopy of the relevant public health forms. These forms are then summarized in study data extraction forms and entered into a single secure database. Data are verified by a supervisor comparing extraction forms to the chart forms, and the database electronic records to the extraction forms.
Analysis
The primary outcome of interest is the overall yield of secondary TB cases from either the new active program compared with the passive routine program and associated costs of each. Univariate analyses will be performed to describe population characteristics. Analysis will be undertaken according the principles of intention-to-treat (ITT), using data collected from individual TB case records at randomized clinics, such that contacts detected as secondary cases will be assigned to the intervention or comparator in their clinic at that time period. A marginal logistic regression model will be estimated using Generalized Estimated Equations (GEE ). The GEE will be modeled using a logit link function, and a robust variance estimation which is robust to misspecification of the correlation structure. Analysis will be at the unit of the individual accounting for the clustering by clinic. Covariates included in the model will include individual level age, gender, previous TB treatment, index TB case smear positivity gradient and clinic level covariates. The treatment effect will be an odds ratio of the time to case detection in the intervention group (ACF) in comparison to the comparator (PCF).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lena Shah, MSc, PhD(c)
- Phone Number: 514-357-4913
- Email: lena.shah@mail.mcgill.ca
Study Locations
-
-
Lima
-
San Martin de Porres, Lima, Peru, Ing. 42
- Recruiting
- Instituto de Medicina Tropicales "Alexander von Humboldt", Universidad Peruana Cayetano Heredia
-
Contact:
- Maximo Grados, MSc
- Email: maximo.grados@upch.pe
-
Principal Investigator:
- Lena Shah, MSc., PhD(c)
-
Principal Investigator:
- Eduardo Gotuzzo, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Index TB cases will be included if they are ≥15 years old, sputum smear positive and identify at least one household contact on questioning. All TB household contacts identified will be included if they meet the program household contact definition and have not previously been diagnosed or under current TB treatment.
Exclusion Criteria:
- Patients who are receiving treatment from private clinics, are in prison or otherwise institutionalized, will be excluded from enrollment as index cases as per current DISA NTP practice. TB cases reported outside of the Ministry of Health clinics will not be included unless they are referred and enter the Ministry of Health system and the DOTS program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Passive Household Contact Evaluation
Passive case finding refers to the current National TB program of voluntary self-reporting of symptomatic patients to the health system for diagnosis of TB and initiation of effective chemotherapy
|
|
Experimental: Active Household Contact Evaluation
The intervention program includes households visits of all newly diagnosed TB cases enrolled in TB treatment within a DISA NTP clinic in SJL district.
During the home visit health staff will evaluate all household contacts for symptoms of active TB.
Any person reporting cough for >14 days will be asked to provide a spot sputum for microscopy and referred to the clinic for chest x-ray and clinical evaluation.
All household contacts ≤19 years will be referred to the clinic for chest x-ray, pediatric clinical evaluation and initiation of treatment for active or latent TB as required.
Counseling including TB infection control practices and importance of diagnosis and treatment completion for TB cases will be provided to household members.
|
Active evaluation of TB household contacts will be introducted as a new intervention in the district.
The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Active Tuberculosis
Time Frame: 6 months
|
Evaluation of active Tuberculosis in exposed household contacts of TB patients enrolled in treatment
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jay S Kaufman, PhD, McGill University
- Principal Investigator: Timothy F Brewer, MD, University of California, Los Angeles
- Principal Investigator: Lena Shah, MSc., PhD(c), McGill University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIHR-235353
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Active Household Contact Evaluation
-
Johns Hopkins Bloomberg School of Public HealthPerinatal HIV Research Unit of the University of the Witswatersrand; Setshaba...Active, not recruiting
-
Temple UniversityPennsylvania Department of HealthActive, not recruitingRespiratory Viral Infection | Gastrointestinal InfectionUnited States
-
University of LausanneCompletedGeriatric Syndrome | Functional AbilitySwitzerland
-
Johnson & Johnson Vision Care, Inc.Completed
-
Centre Hospitalier Universitaire de NīmesRecruitingPain | Chronic Pain | Surgical Procedures, OperativeFrance
-
University of Western Ontario, CanadaCompleted
-
University of Massachusetts, WorcesterNational Heart, Lung, and Blood Institute (NHLBI); Brown University; The Miriam... and other collaboratorsCompletedObesity Prevention | Child Behavior Problems | Parenting SkillsUnited States
-
Geriatric Education and Research InstituteSingapore General Hospital; Changi General Hospital; Sengkang General Hospital; Alexandra Hospital and other collaboratorsCompletedFrail Elderly Syndrome | Frailty | Frailty SyndromeSingapore
-
Hospices Civils de LyonRecruitingContact Dermatitis | Contact Dermatitis Irritant | Contact Dermatitis, AllergicFrance
-
University Hospital, BordeauxCelgeneRecruitingMultiple SclerosisFrance